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the use of masks, considering compli-
ance with this advice unlikely because 
many Muslims believe that covering 
the face during the Hajj is prohibited 
and because masks need to be of high 
quality and changed at least every 6 
hours to remain effective (7). Recent 
studies demonstrated that surgical and 
N95 masks were equally effective in 
preventing spread of PCR-detectable 
inﬂ  uenza virus when used by infected 
patients. These masks also were po-
tentially effective at preventing respi-
ratory virus acquisition by household 
contacts of infected persons when 
worn by healthy persons. However, 
effectiveness depended largely on ad-
herence to mask use (8,9).
Maintenance of good hand hy-
giene is also effective in reducing 
spread of respiratory infection. The 
World Muslim League has issued a 
fatwa allowing use of alcohol-based 
hand-rubs on skin as a disinfectant 
(10).
The demonstration of high ac-
ceptability of simple physical mea-
sures to prevent ARI encourages the 
education of pilgrims during the pre-
travel encounter. The results also sup-
port conclusion that masks, hand-rubs, 
and disposable handkerchiefs should 
be provided to pilgrims, along with 
strong advice about the risk for ARI, 
to increase adherence to prevention 
measures.
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Persistent 
Extended-Spectrum 
β-Lactamase 
Urinary Tract 
Infection
To the Editor: Uncomplicated 
urinary tract infections (UTIs) in oth-
erwise healthy adults are usually treat-
ed empirically because the causative 
microbe is highly predictable: 80%–
90% are caused by Escherichia coli. 
In addition, short courses of therapy 
(1 day or 3 days) are usually complet-
ed before laboratory results become 
available. In the past decade, reports 
of community-acquired, extended-
spectrum  β-lactamase (ESBL)–pro-
ducing E. coli isolates have increased 
worldwide, but they are still uncom-
mon in the United States (1), where re-
ported cases are generally associated 
with hospitals. An early report of true 
community-acquired ESBL-producing 
E. coli infections in the United States 
was published in 2007 (2). We report 
a case of community-acquired lower 
UTI caused by ESBL-producing and 
multidrug resistant E. coli in an oth-
erwise healthy college-aged woman 
who had no hospital exposure. De-
spite proper treatment, her infection 
persisted subclinically and symptoms 
recurred 2 months later.
The patient was an afebrile 24-
year-old female college student who 
had visited her university health ser-
vice, where she was recruited into a 
clinical trial investigating the effects 
of cranberry juice on UTIs. Inclusion 
in the study required that participants 
have UTI signs and symptoms, posi-
tive urine culture, and physician diag-
nosis. Participants provided self-col-
lected vaginal, rectal, and midstream 
urine specimens at the time of enroll-
ment and at 3- and 6-month follow-up 
or UTI recurrence. Study protocol was 
approved by the University of Michi-
gan Institutional Review Board.
E. coli was isolated from all 
specimens collected from the patient 
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at the time of enrollment; urinalysis 
conﬁ   rmed pyuria (>100 leukocytes/
high power ﬁ  eld). Also at the time of 
enrollment, the patient reported no an-
timicrobial drug treatment during the 
previous 4 weeks, no history of hospi-
talization, no urethral catheterization, 
and no sexually transmitted infection 
(conﬁ  rmed by medical record review). 
A 7-day regimen of nitrofurantoin was 
prescribed.
After 53 days, the patient returned 
to the health service with recurring 
UTI symptoms and was treated with 
a 3-day regimen of trimethoprim–
sulfamethoxazole; no urine specimen 
was submitted at that time. However, 
E. coli isolates were recovered from 
recurrence urine and rectal specimens 
collected within 48 hours according 
to the clinical trial protocol. All E. 
coli isolates collected at the time of 
enrollment (n = 3) and recurrence (n 
= 2) appeared morphologically and 
phenotypically identical (API Rap-
id 20E; bioMérieux, Durham, NC, 
USA). Genotyping using enterobac-
terial repetitive intergenic consensus 
(ERIC) PCR with an ERIC-2 primer 
showed a shared ERIC type, indicat-
ing identity (Figure). When tested for 
antimicrobial drug susceptibility (Vi-
tek 2; bioMérieux), all 5 isolates were 
identiﬁ   ed as ESBL-producers and 
were resistant to β-lactams: ampicil-
lin, cefazolin, ceftriaxone (MIC >64 
μg/mL), aztreonam, and piperacillin. 
After an ESBL conﬁ  rmatory test, rec-
ommended by the Clinical and Labo-
ratory Standards Institute (3), showed 
positive results, the isolates were also 
considered resistant to ceftazidime 
(MIC 1–4 μg/mL) and cefepime. 
Disk diffusion indicated susceptibil-
ity to cefoxitin. The isolates were 
also resistant to ﬂ  uoroquinolones, 
tetracycline, and trimethoprim–
sulfamethoxazole but susceptible to 
aminoglycosides, carbapenems, and 
nitrofurantoin. Isolates from the time 
of enrollment had intermediate sus-
ceptibility to amoxicillin–clavulanate 
(MIC 16 μg/mL), but isolates from 
the recurrence episode were resistant 
(MIC 32 μg/mL).
Although the patient’s initial UTI 
was treated adequately with nitro-
furantoin, the infection recurred, im-
plying that it remained in a reservoir, 
not uncommon for uncomplicated 
UTIs (4,5). Alternative antimicrobial 
drug treatment for outpatients with 
ESBL-producing Enterobacteriaceae 
is limited. Carbapenems remain the 
most effective drugs (6) but must be 
administered intravenously or intra-
muscularly (3). The reported efﬁ  cacy 
of fosfomycin (7) suggests an option, 
but because agar dilution is the only 
recommended testing method, use 
of this drug in the United States is 
hindered. Use of antimicrobial drugs 
that concentrate in urine remains 
controversial as long as resistance 
is interpreted by MIC (blood-level 
resistance).
PCR detected β-lactamase resis-
tance genes in all isolates, identifying 
them as ESBL positive when CTX-M 
consensus primer PCR was used but 
negative with TEM and SHV. Se-
quence analysis of the ampliﬁ  ed gene 
showed that it encoded a CTX-M-15
–like ESBL.
This isolate’s increasing resis-
tance to a β-lactamase–inhibitor com-
bination, amoxicillin–clavulanate, 
suggested the possibility of inducible 
AmpC  β-lactamase production. A 
negative AmpC disk test (with Tris/
EDTA, cefoxitin, and E. coli ATCC 
25922) refuted a plasmid-mediated 
AmpC β-lactamase (6); the remaining 
possible resistance mechanisms were 
hyperproduction of β-lactamase or an 
inhibitor-resistant penicillinase.
For the patient reported here, the 
multiple drug–resistant strain persisted 
for at least 53 days despite appropriate 
treatment with antimicrobial drugs. 
Furthermore, medical record review 
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Figure. Enterobacterial repetitive intergenic consensus typing of extended-spectrum 
β-lactamase–producing Escherichia coli isolated from index (0) and recurring (R) urine (U), 
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found an additional UTI caused by E. 
coli 12 weeks later. Thus, because of 
the long duration of carriage of this 
highly resistant strain, potential for 
transmission to others is high.
The low number of previous re-
ports of community-acquired ESBL in 
the United States does not necessarily 
suggest low community prevalence. 
Reports of ESBL-producer bacteremia 
in patients visiting emergency rooms 
suggests earlier and wider incidence 
(8). Returning to the practice of regu-
larly culturing urine samples is difﬁ  -
cult to justify; however, without ongo-
ing surveillance to detect and control 
ESBL resistance, prevalence can only 
be expected to rise. 
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Leishmania killicki 
Imported from 
Tunisian Desert
To the Editor: In North Africa, 
cutaneous leishmaniasis (CL) is a 
widespread zoonosis transmitted by 
sandﬂ   ies. In Tunisia, 3 Leishmania 
species are responsible for CL: L. ma-
jor, L. infantum, and L. killicki.  L. ma-
jor causes 2,000–4,000 zoonotic CL 
infections each year. L. infantum, the 
usual agent of visceral leishmaniasis, 
may be implicated in sporadic CL in 
northern Tunisia (dermotropic strains 
coexist with viscerotropic strains of 
L. infantum in these areas). L. killicki 
was ﬁ  rst described in the desert region 
of Tataouine, Tunisia, in 1986 (1) and 
is the agent of chronic CL. We report 
a case of chronic CL caused by L. kil-
licki, imported to Europe by a woman 
who had traveled to Tunisia.
 A 76-year-old woman, with no 
relevant medical history, sought treat-
ment from a dermatologist in Greno-
ble, France, for a cutaneous lesion on 
her right arm. This lesion had appeared 
2 months after she returned from a July 
2007 trip to Tunisia, where she spent 2 
weeks in the desert riding camels and 
sleeping under a tent. The cutaneous 
lesion was isolated, round, 10 mm in 
diameter, ulcerative, surrounded by 
inﬂ  ammation, and painless; no lymph-
adenopathy was found. The patient 
had no lesions on her mucous mem-
branes and no concomitant general 
signs or symptoms. Given the absence 
of substantial signs or symptoms, the 
patient had paid no particular attention 
to this lesion until it became second-
arily infected with bacteria. The sec-
ondary infection resolved after treat-
ment with antimicrobial drugs, but the 
lesion persisted and a diagnosis of CL, 
presumably caused by L. major, was 
suggested.
Histologic investigation of a skin 
scraping showed amastigotes of Leish-
mania spp., but no further identiﬁ  ca-
tion was done at that time. No treat-
ment was given because the lesion was 
isolated and on the arm and because 
L. major lesions frequently heal spon-
taneously. After 2 months, the lesion 
had not healed, and Leishmania amas-
tigotes were still found in scrapings. 
After 8 months, the lesion became in-
ﬂ  amed, and a skin scraping sample was 
sent to the National Reference Center 
of Leishmania in Montpellier, France. 
DNA was extracted, and L. killicki 
was identiﬁ  ed by genotyping. Various 
therapeutic options were considered, 
but no clear treatment recommenda-
tions were found. Parenteral therapy 
(pentavalent antimonials, pentamidine 
isethionate, or amphotericin B) was 
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